20 September 2018 - - US-based clinical-stage biotherapeutics company Tmunity Therapeutics, Inc has appointed Moji James to general counsel and executive vice president, the company said.

James formerly served as senior vice president, general counsel and corporate secretary of Iroko Pharmaceuticals where she managed various functions including legal, compliance, human resources and corporate communications.

In her role at Tmunity, James will be responsible for all legal affairs, and will be an advocate for the company's core values while helping to grow and protect its assets and intellectual property.

Prior to her role at Iroko, James held positions of increasing responsibility at Wyeth Pharmaceuticals and Pfizer, where she served as the primary business lawyer for several therapeutic areas, including transplant, neuroscience and US vaccines and supported the development and launch of several key products.

Before joining Wyeth, she was a litigator at major law firms including Shearman and Sterling in New York, focusing her practice on complex commercial and securities issues.

Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases.

Integrating a foundational collaboration with the University of Pennsylvania and the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders (Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new centre of gravity in translational T cell medicine.

The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body, with an initial focus in cancer with two programs currently in the clinic.

Headquartered in Philadelphia, Tmunity utilises laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in Norristown, Pennsylvania, to pursue process improvement and production scale-up in support of clinical development of its T cell therapies.